NightHawk Biosciences, Inc.(NYSE Amex Equities : HTBX)
HTBX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.07%||166.35||0.7%||$1322.99m|
|LLY||Eli Lilly & Co.||-0.29%||333.20||1.1%||$1039.75m|
|BMY||Bristol-Myers Squibb Co.||0.00%||72.06||1.0%||$784.71m|
|MRK||Merck & Co., Inc.||-0.82%||86.08||0.7%||$697.20m|
|ALNY||Alnylam Pharmaceuticals, Inc.||0.00%||210.76||8.2%||$210.83m|
|GBT||Global Blood Therapeutics, Inc.||0.00%||68.11||5.4%||$190.67m|
|NVO||Novo Nordisk A/S||1.29%||100.66||0.1%||$177.86m|
|HZNP||Horizon Therapeutics Plc||-0.55%||63.49||5.4%||$169.03m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||-0.42%||151.31||0.0%||$157.49m|
NightHawk Biosciences, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.